PTC Therapeutics, Inc. — Q2 2014 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2014. Unaudited financial statements; amounts below are in U.S. dollars. PTC is a clinical-stage biopharmaceutical company developing ataluren (Translarna) and other small-molecule drug candidates. It had no product sales revenue.
Financial performance
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $1.7 million | $6.9 million | $10.9 million | $14.0 million |
| Research and development | $18.3 million | $14.7 million | $34.2 million | $26.0 million |
| General and administrative | $8.7 million | $6.6 million | $16.3 million | $11.1 million |
| Operating loss | $25.4 million | $14.5 million | $39.6 million | $23.0 million |
| Net loss | $25.1 million | $14.6 million | $39.2 million | $29.3 million |
| Net loss per share, basic and diluted | $0.86 | $5.51 | $1.40 | $33.26 |
Q2 revenue fell 76%, mainly because less previously deferred collaboration revenue was recognized; grant revenue also declined. First-half revenue fell 22%, despite $7.5 million of Roche milestone revenue recognized in Q1 after initiation of an SMA Phase 1 program. First-half R&D rose 32% and G&A rose 47%, reflecting clinical development, manufacturing, regulatory and pre-commercial spending, as well as higher share-based compensation. Q2 net loss widened year over year. First-half 2013 net loss per share included a deemed dividend and recapitalization gain; 2014 did not.
Cash and cash equivalents were $21.2 million and marketable securities were $205.7 million at June 30, totaling $226.9 million. Current assets were $230.3 million versus current liabilities of $11.6 million. Total liabilities were $13.8 million and stockholders’ equity was $223.8 million. No material debt remained on the balance sheet; the secured debt facility had been repaid in July 2013.
For the first six months, operating cash use was $32.2 million, investing cash use was $80.4 million (primarily net purchases of marketable securities), and financing provided $118.4 million, principally from the February 2014 follow-on offering. Cash increased $5.8 million. Management estimated existing cash, securities and expected collaboration funding would support operating and capital needs into mid-2016, subject to assumptions.
Business developments, outlook and risks
- Translarna/nmDMD: After quarter-end, on August 4, 2014, the European Commission granted conditional marketing authorization for ambulatory patients aged five and older with nonsense-mutation Duchenne muscular dystrophy in the EEA. Authorization requires annual review and completion of the ACT DMD confirmatory Phase 3 trial. PTC expected initial top-line ACT DMD data in the second half of 2015.
- PTC planned selected-country European commercial launches in the first half of 2015, subject to country-specific market access, pricing and reimbursement processes; submissions were expected to begin in Q4 2014. Some processes may take more than 18 months. The company did not expect significant nmDMD commercial revenue in 2014.
- Other programs: The global ACT CF confirmatory Phase 3 study began near the end of Q2; enrollment was expected to finish in the second half of 2015, with initial data about a year later. PTC planned a Phase 2 proof-of-concept nmMPS I study in Q4 2014. Roche’s SMA Phase 1a study reported preliminary tolerability and dose-dependent pharmacodynamic findings; a multiple-dose patient study was in preparation. PTC596 remained in preclinical development, and PTC expected to select an antibacterial development candidate later in 2014.
- Management expected substantially higher expenses for commercialization, infrastructure, clinical trials and pipeline development, and stated that additional financing might be needed. If financing is unavailable on acceptable terms, PTC could delay, reduce or end programs or commercialization efforts.
- Key risks include confirmatory-trial results and enrollment, annual renewal of conditional authorization, pricing and reimbursement delays, limited eligible patient populations, safety and regulatory requirements, manufacturing and third-party dependence, competition, and intellectual-property challenges. Prior trials did not meet their primary efficacy endpoints at the prespecified statistical significance level; favorable interpretations included retrospective and subgroup analyses. The filing also describes prior EMA inspection findings at clinical sites and corrective actions proposed by PTC.
- Contractual commitments included $4.2 million of operating lease obligations through February 2019. Potential Wellcome Trust development and regulatory milestones could total up to $68.9 million, plus royalties if products are commercialized; these are contingent, not current debt. The company reported ordinary-course patient-access-related legal matters and did not expect pending matters to have a material adverse impact. Management concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Progress, enrollment and results for ACT DMD and ACT CF, including whether trial outcomes satisfy regulators’ requirements.
- Renewal conditions for the EEA authorization and country-by-country timing, pricing, reimbursement and launch execution.
- Actual cash burn and financing needs against management’s mid-2016 runway estimate, particularly as commercial and clinical spending increases.
- Whether eligible-patient estimates, market access and product uptake support the commercial opportunity under the restricted nmDMD label.
- Clinical safety, manufacturing capacity, third-party performance, and material developments in the disclosed intellectual-property and compliance risks.